Catheter Precision Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
VTAK$0.15-0.7%Stored close · as of Oct 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current Assets | ||
| Cash and cash equivalents | $1,268 | $3,565 |
| Accounts receivable | 107 | 137 |
| Inventories | 32 | 44 |
| Prepaid expenses and other current assets | 307 | 415 |
| Total current assets | 1,714 | 4,161 |
| Property and equipment, net | 111 | 70 |
| Operating lease right-of-use assets, net | 127 | 179 |
| Intangible assets, net | 24,785 | 26,318 |
| Other non-current assets | 8 | 8 |
| TOTAL ASSETS | $26,745 | $30,736 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current Liabilities | ||
| Accounts payable | $708 | $464 |
| Accrued expenses | 1,497 | 1,733 |
| Notes payable | 249 | 184 |
| Interest payable to related parties | 16 | — |
| Current portion of royalties payable | 17 | — |
| Current portion of operating lease liabilities | 99 | 91 |
| Total current liabilities | 2,586 | 2,472 |
| Royalties payable | 9,797 | 6,974 |
| Notes payable due to related parties | 1,500 | — |
| Operating lease liabilities | 36 | 97 |
| Total liabilities | 13,919 | 9,543 |
| Commitments and contingencies (see Note 17) | ||
| Stockholders' Equity | ||
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized | ||
| Series A Convertible Preferred Stock, $0.0001 par value, 7,203 shares designated; 0 and 4,578 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | — | — |
| Series X Convertible Preferred Stock, $0.0001 par value, 15,404 shares designated; 12,656 shares issued and outstanding as of September 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value, 30,000,000 shares authorized; 3,452,652 and 702,662 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | — | — |
| Additional paid-in capital | 299,550 | 296,902 |
| Accumulated deficit | (286,724) | (275,709) |
| Total stockholders' equity | 12,826 | 21,193 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $26,745 | $30,736 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.